Literature DB >> 24639337

Restrictive lung involvement in facioscapulohumeral muscular dystrophy.

Michele A Scully1, Katy J Eichinger, Colleen M Donlin-Smith, Rabi Tawil, Jeffery M Statland.   

Abstract

INTRODUCTION: Few studies have evaluated the frequency or predisposing factors for respiratory involvement in facioscapulohumeral muscular dystrophy type 1 (FSHD1) and type 2 (FSHD2).
METHODS: We performed a prospective cross-sectional observational study of 61 genetically confirmed FSHD participants (53 FSHD1 and 8 FSHD2). Participants underwent bedside pulmonary function testing in sitting and supine positions, a standard clinical history and physical assessment, and manual muscle testing.
RESULTS: Restrictive respiratory involvement was suggested in 9.8% (95% confidence interval 2.4-17.3): 7.5% FSHD1 and 25.0% FSHD2 (P = 0.17). Participants with testing suggestive of restrictive lung involvement (n = 6) were more severely affected (P = 0.005), had weaker hip flexion (P = 0.0007), and were more likely to use a wheelchair (P = 0.01).
CONCLUSIONS: Restrictive respiratory involvement should be considered in all moderate to severely affected FSHD patients with proximal lower extremity weakness. The higher frequency of restrictive lung disease in FSHD2 seen here requires confirmation in a larger cohort of FSHD2 patients. © Published 2014 by Wiley Periodicals, Inc.

Entities:  

Keywords:  FSHD1; FSHD2; muscle disease; prevalence studies; respiratory disease

Mesh:

Year:  2014        PMID: 24639337      PMCID: PMC4142113          DOI: 10.1002/mus.24218

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  17 in total

1.  Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy.

Authors:  C Wijmenga; J E Hewitt; L A Sandkuijl; L N Clark; T J Wright; H G Dauwerse; A M Gruter; M H Hofker; P Moerer; R Williamson
Journal:  Nat Genet       Date:  1992-09       Impact factor: 38.330

2.  The maximal expiratory flow-volume curve. Normal standards, variability, and effects of age.

Authors:  R J Knudson; R C Slatin; M D Lebowitz; B Burrows
Journal:  Am Rev Respir Dis       Date:  1976-05

Review 3.  Facioscapulohumeral muscular dystrophy and DUX4: breaking the silence.

Authors:  Silvère M van der Maarel; Rabi Tawil; Stephen J Tapscott
Journal:  Trends Mol Med       Date:  2011-02-01       Impact factor: 11.951

4.  Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society.

Authors: 
Journal:  Am Rev Respir Dis       Date:  1991-11

5.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

6.  Correlation between fragment size at D4F104S1 and age at onset or at wheelchair use, with a possible generational effect, accounts for much phenotypic variation in 4q35-facioscapulohumeral muscular dystrophy (FSHD)

Authors:  P W Lunt; P E Jardine; M C Koch; J Maynard; M Osborn; M Williams; P S Harper; M Upadhyaya
Journal:  Hum Mol Genet       Date:  1995-05       Impact factor: 6.150

7.  Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. The FSH DY Group.

Authors:  K E Personius; S Pandya; W M King; R Tawil; M P McDermott
Journal:  Phys Ther       Date:  1994-03

8.  Spirometry in normal subjects in sitting, prone, and supine positions.

Authors:  G M Vilke; T C Chan; T Neuman; J L Clausen
Journal:  Respir Care       Date:  2000-04       Impact factor: 2.258

9.  Ventilatory support in facioscapulohumeral muscular dystrophy.

Authors:  M Wohlgemuth; E L van der Kooi; R G van Kesteren; S M van der Maarel; G W Padberg
Journal:  Neurology       Date:  2004-07-13       Impact factor: 9.910

10.  Profiles of neuromuscular diseases. Facioscapulohumeral muscular dystrophy.

Authors:  D D Kilmer; R T Abresch; M A McCrory; G T Carter; W M Fowler; E R Johnson; C M McDonald
Journal:  Am J Phys Med Rehabil       Date:  1995 Sep-Oct       Impact factor: 2.159

View more
  11 in total

Review 1.  Facioscapulohumeral Dystrophy.

Authors:  Leo H Wang; Rabi Tawil
Journal:  Curr Neurol Neurosci Rep       Date:  2016-07       Impact factor: 5.081

2.  Muscle pathology grade for facioscapulohumeral muscular dystrophy biopsies.

Authors:  Jeffrey M Statland; Bharati Shah; Don Henderson; Silvere Van Der Maarel; Stephen J Tapscott; Rabi Tawil
Journal:  Muscle Nerve       Date:  2015-06-18       Impact factor: 3.217

3.  Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy.

Authors:  Katy Eichinger; Chad Heatwole; Susanne Heininger; Nikia Stinson; Carly Matichak Stock; Carla Grosmann; Kathryn R Wagner; Rabi Tawil; Jeffrey M Statland
Journal:  Muscle Nerve       Date:  2016-12-05       Impact factor: 3.217

Review 4.  Facioscapulohumeral Muscular Dystrophy: Update on Pathogenesis and Future Treatments.

Authors:  Johanna Hamel; Rabi Tawil
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

5.  Respiratory involvement in ambulant and non-ambulant patients with facioscapulohumeral muscular dystrophy.

Authors:  Sandra Moreira; Libby Wood; Debbie Smith; Chiara Marini-Bettolo; Michela Guglieri; Grace McMacken; Geraldine Bailey; Anna Mayhew; Robert Muni-Lofra; Gail Eglon; Maggie Williams; Volker Straub; Hanns Lochmüller; Teresinha Evangelista
Journal:  J Neurol       Date:  2017-05-26       Impact factor: 4.849

Review 6.  Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update.

Authors:  Teresa Schätzl; Lars Kaiser; Hans-Peter Deigner
Journal:  Orphanet J Rare Dis       Date:  2021-03-12       Impact factor: 4.123

7.  Long-term follow-up of respiratory function in facioscapulohumeral muscular dystrophy.

Authors:  Sjan Teeselink; Sanne C C Vincenten; Nicol C Voermans; Jan T Groothuis; Jonne Doorduin; Peter J Wijkstra; Corinne G C Horlings; Baziel G M van Engelen; Karlien Mul
Journal:  J Neurol       Date:  2022-02-11       Impact factor: 4.849

8.  Assessment of diaphragm motion using ultrasonography in a patient with facio-scapulo-humeral dystrophy: A case report.

Authors:  Abdallah Fayssoil; Tanya Stojkovic; Adam Ogna; Pascal Laforet; Helene Prigent; Frederic Lofaso; David Orlikowski; Guillaume Bassez; Bruno Eymard; Anthony Behin
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

Review 9.  DUX4 Signalling in the Pathogenesis of Facioscapulohumeral Muscular Dystrophy.

Authors:  Kenji Rowel Q Lim; Quynh Nguyen; Toshifumi Yokota
Journal:  Int J Mol Sci       Date:  2020-01-22       Impact factor: 5.923

10.  A case of type 1 facioscapulohumeral muscular dystrophy (FSHD) with restrictive ventilatory defect and congestive heart failure.

Authors:  Nobutoshi Morimoto; Mizuki Morimoto; Yoshiaki Takahashi; Motonori Takamiya; Ichizo Nishino; Koji Abe
Journal:  eNeurologicalSci       Date:  2020-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.